Segment Reporting (Details) |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
|
Jun. 30, 2026
USD ($)
|
Mar. 31, 2026
USD ($)
|
Jun. 30, 2025
USD ($)
|
Mar. 31, 2025
USD ($)
|
Jun. 30, 2026
USD ($)
Segment
|
Jun. 30, 2025
USD ($)
|
|
| Segment Reporting [Abstract] | ||||||
| Number of operating segments | Segment | 1 | |||||
| Number of reportable segments | Segment | 1 | |||||
| Segment Expenses [Abstract] | ||||||
| Total operating expenses | $ 6,496,734 | $ 7,623,351 | $ 13,017,821 | $ 16,729,109 | ||
| Interest income | 125,405 | 333,624 | 312,219 | 711,473 | ||
| Interest expense | (3,379,246) | (2,144,481) | (4,394,029) | (3,075,359) | ||
| Benefit from income taxes | 0 | 0 | 0 | 1,169,820 | ||
| Net loss | (9,750,575) | $ (7,349,056) | (9,434,208) | $ (8,488,967) | (17,099,631) | (17,923,175) |
| Operating Segment [Member] | PDS [Member] | ||||||
| Segment Expenses [Abstract] | ||||||
| Salaries and benefits | 3,377,524 | 2,857,617 | 6,775,882 | 6,686,838 | ||
| Professional fees | 1,111,476 | 1,278,581 | 2,018,160 | 2,405,627 | ||
| General administrative expenses | 309,370 | 387,897 | 651,869 | 732,251 | ||
| Clinical development expenses | 1,084,716 | 2,017,145 | 2,353,900 | 2,455,049 | ||
| Other development expenses | 613,648 | 1,082,111 | 1,218,010 | 4,449,344 | ||
| Total operating expenses | 6,496,734 | 7,623,351 | 13,017,821 | 16,729,109 | ||
| Net loss | (9,750,575) | (9,434,208) | (17,099,631) | (17,923,175) | ||
| Reconciling Item [Member] | ||||||
| Segment Expenses [Abstract] | ||||||
| Interest income | 125,405 | 333,624 | 312,219 | 711,473 | ||
| Interest expense | (3,379,246) | (2,144,481) | (4,394,029) | (3,075,359) | ||
| Benefit from income taxes | $ 0 | $ 0 | $ 0 | $ 1,169,820 | ||
| X | ||||||||||
- Definition Amount of expense associated with the process of bringing a new drug or medical device to market, including preclinical research, clinical trials, and regulatory submissions. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development classified as other. No definition available.
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of interest expense classified as nonoperating. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of general and administrative expense classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|